Renal cell carcinoma (RCC) is the third most common cancer of the urinary system. There is a pressing need for specific biomarkers for advanced/metastatic RCC to enhance diagnostic accuracy and ...
Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...